Factors influencing the coping strategies of liver cancer patients undergoing transarterial chemoembolization

2021 ◽  
Author(s):  
Su‐Chih Chen ◽  
Shu‐Fang Wu ◽  
Tsae‐Jyy Wang ◽  
John Rosenberg ◽  
Yu‐Ying Lu ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Coping Strategies ◽  
Cancer Patients ◽  
Transarterial Chemoembolization ◽  
Factors Influencing

Resilience and Its Predictors Among Chinese Liver Cancer Patients Undergoing Transarterial Chemoembolization

2019 ◽  
Vol 42 (5) ◽  
pp. E1-E9 ◽  
Author(s):  
Caixia Li ◽  
Huijuan Lu ◽  
Wei Qin ◽  
Xiaorong Li ◽  
Jingxian Yu ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Patients ◽  
Transarterial Chemoembolization

scholarly journals The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study

2020 ◽  
Vol 28 (3) ◽  
pp. 249-271
Author(s):  
Zhiyi Peng ◽  
Guohong Cao ◽  
Qinming Hou ◽  
Ling Li ◽  
Shihong Ying ◽  
...  
Keyword(s):  
Cohort Study ◽  
Liver Cancer ◽  
Liver Function ◽  
Portal Vein ◽  
Cancer Patients ◽  
Transarterial Chemoembolization ◽  
Portal Vein Invasion ◽  
Drug Eluting Beads ◽  
Drug Eluting ◽  
Tace Treatment

This study aimed to investigate the efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating Chinese patients with liver cancer. A total of 367 liver cancer patients from 24 medical centers were consecutively enrolled in this multiple-center, prospective cohort study, including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic cholangiocarcinoma (ICC) cases, and 55 secondary liver cancer cases. All the patients received CalliSpheres® DEB-TACE treatment. Treatment response, overall survival (OS), change of liver function, and adverse events (AEs) were assessed. DEB-TACE treatment achieved 19.9% complete response (CR) and 79.6% objective response rate (ORR), with mean OS of 384 days [95% confidence interval (CI): 375‐393 days]. CR and ORR were both higher in HCC patients compared with primary ICC patients and secondary liver cancer patients, while no difference was discovered in OS. Portal vein invasion was an independent risk factor for CR, while portal vein invasion, previous conventional TACE (cTACE) treatment, and abnormal blood creatinine (BCr) were independent risk factors for ORR. In addition, largest nodule size ≥5.0 cm, abnormal albumin (ALB), and abnormal total bilirubin (TBIL) independently correlated with unfavorable OS. Most liver function indexes were recovered to baseline levels at 1‐3 months after DEB-TACE. Common AEs were pain, fever, vomiting, and nausea; most of them were at mild grade. CalliSpheres® DEB-TACE is efficient and well tolerated in Chinese liver cancer patients. Portal vein invasion, previous cTACE treatment, largest nodule size, abnormal BCr, ALB, and TBIL correlate with worse prognosis independently.

scholarly journals Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients

BMC Cancer ◽  
2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Nikolaus Kohles ◽  
Dorothea Nagel ◽  
Dietrich Jüngst ◽  
Jürgen Durner ◽  
Petra Stieber ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Patients ◽  
Transarterial Chemoembolization

DNase is a prognostic marker in liver cancer patients receiving transarterial chemoembolization therapy

2013 ◽  
Vol 51 (01) ◽  
pp. 80-83 ◽  
Author(s):  
Nikolaus Kohles ◽  
Dorothea Nagel ◽  
Dietrich Jüngst ◽  
Petra Stieber ◽  
Stefan Holdenrieder
Keyword(s):  
Liver Cancer ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Transarterial Chemoembolization

Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy

Tumor Biology ◽  
2012 ◽  
Vol 33 (6) ◽  
pp. 2401-2409 ◽  
Author(s):  
Nikolaus Kohles ◽  
Dorothea Nagel ◽  
Dietrich Jüngst ◽  
Petra Stieber ◽  
Stefan Holdenrieder
Keyword(s):  
Cell Death ◽  
Liver Cancer ◽  
Cancer Patients ◽  
Predictive Value ◽  
Transarterial Chemoembolization ◽  
Immunogenic Cell Death

scholarly journals Callispheres® Drug-Eluting Beads Transarterial Chemoembolization Might be an Efficient and Safety Down-Staging Therapy in Unresectable Liver Cancer Patients

2021 ◽  
Author(s):  
Ning Peng ◽  
Linfeng Mao ◽  
Yiwen Tao ◽  
Kaiyin Xiao ◽  
Guandou Yuan ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Patients ◽  
Transarterial Chemoembolization ◽  
Objective Response ◽  
Liver Volume ◽  
Complete Response ◽  
Tumor Diameter ◽  
Kaplan Meier ◽  
Drug Eluting Beads ◽  
Drug Eluting

Abstract Purpose: The purpose was to explore the effect of drug-eluting beads transarterial chemoembolization (DEB-TACE) on down-staging in unresectable liver cancer patients.Methods: 15 unresectable liver cancer patients received DEB-TACE as a down-staging treatment before hepatectomy were enrolled. Data (including demographics, histories, clinical features at diagnosis and cycles of DEB-TACE before hepatectomy) were collected. Treatment response was evaluated at one month after DEB-TACE. Tumor diameter was evaluated by abdominal computed tomography scan. The residual liver volume was evaluated by IQQA liver system, Relapse-free survival (RFS) and overall survival (OS) were calculated by Kaplan-Meier curves.Results: After DEB-TACE, 3 (20.0%) patients achieved complete response (CR) and 10 (66.7%) patients achieved objective response rate (ORR), meanwhile, 5 (27.8%) tumors achieved CR and 12 (66.7%) tumors achieved ORR. Tumor diameter was decreased after DEB-TACE compared to before DEB-TACE (9.4±3.3 vs. 5.4±3.5 cm) (P<0.01). As to residual liver volume, it was increased after DEB-TACE compared to before DEB-TACE (1066.2 cm3 vs. 1172.5 cm3) (P=0.007). More importantly, 15 (100%) patients could receive resection after DEB-TACE, (including 14 (93.3%) patients with curative resection and 1 (6.7%) patient with palliative resection). For survival, the median RFS was 26.0 months, and the percentage of 5-year accumulating RFS was 20%. As to OS, the median OS was 54.5 months, and the percentage of 5-year accumulating OS was 40%. For safety profiles, 5 patients had postoperative pain, 7 patients had fever, and 1 had nausea and vomiting.Conclusion: DEB-TACE might be an efficient and safety down-staging treatment in unresectable liver cancer patients.

Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy

Tumor Biology ◽  
2011 ◽  
Vol 33 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Nikolaus Kohles ◽  
Dorothea Nagel ◽  
Dietrich Jüngst ◽  
Jürgen Durner ◽  
Petra Stieber ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Patients ◽  
Transarterial Chemoembolization ◽  
Serum Biomarkers ◽  
Prognostic Relevance
Sign in / Sign up

Export Citation Format

Share Document